Explosive growth and a genuine basing setup, sitting next to a swing to loss and an open ASIC investigation the company’s own presentation doesn’t mention
Full BGS 20 Analysis · FY2025 Result & FY2026 Investor Presentation (August 2026) · Prepared 4 September 2026
Live Price: ~$1.76 | Market Cap (est.): ~$1.63bn | Shares on Issue: 924.09m
Sector: Defence Technology, Counter-Drone (C-UxS) | Type of Trade: Speculative, Reduced Size
Strategy: BGS 20 | Bias: Cautiously Constructive, Early-Stage Base
🚩 Read this before the growth numbers below. DroneShield’s own investor presentation is a strong, well-documented growth story, but it stops at FY2025 and doesn’t disclose two things that changed since: independent reporting confirms DRO swung to an estimated ~$32m net loss in 1H2026 despite 74% revenue growth (gross margin compressed from 65% to 60%, partly on a raw material impairment tied to a facility move), and the company is currently cooperating with an ASIC investigation into 2025 announcements and trading activity, outcome unclear. Neither appears in the supplied presentation. Both are weighted into this analysis.
1. Company Overview
DroneShield Limited (ASX: DRO) is a Sydney-headquartered, ASX-listed global leader in AI-powered counter-drone (C-UxS) technology, founded in 2014 by two US scientists and listed on the ASX in 2016. It builds RF detection and defeat sensors, radars, optical sensors, and the DroneSentry-C2 command-and-control software that ties them together, protecting militaries, governments, law enforcement and critical infrastructure operators in 70+ countries. The company explicitly does not offer hard-kill or kinetic effector systems (weapons stations, missiles), positioning itself as a detection-and-defeat technology provider rather than a weapons manufacturer. CEO Angus Bean joined as employee #7 in 2016 and has led since April 2026; Chairman Hamish McLennan joined May 2026, part of a broader board renewal in 2026 (three of six non-executive directors appointed this year).
What bulls see: revenue grew from $10m in 2021 to $216.5m in 2025 (a >20x increase in four years), the global counter-drone TAM is enormous (~$63bn combined military and commercial) against a company still doing low hundreds of millions in revenue, and government funding commitments behind the thematic are real and dated (NATO, the EU, the US, Australia). What bears see: a business that swung from a positive FY2025 to an apparent large 1H2026 loss, compressing margins, a share price already down roughly 74% from its 2024/2025 high near $6.71, a history of large dilutive capital raises when the stock was expensive, and an open regulatory investigation the company’s own promotional materials are silent on.
2. Fundamentals
Figures from the supplied FY2026 investor presentation (FY2025 vs FY2024, and 1H2026 trading update) unless marked otherwise. TTM figures sourced from market data as of late August 2026, since no full FY2026 annual report exists yet.
| Metric | Period | Figure | Change |
|---|---|---|---|
| Revenue | FY2025 vs FY2024 | $216.5m vs $57.5m | +276% |
| Revenue | 1H2026 vs 1H2025 | $125.8m vs $72.3m | +74% |
| FY2026 Outlook (guidance) | Full year | $250m–$270m | +15% to +25% on FY25 |
| FY2026 Committed Revenue | As at 28 Jul 2026 | $206m (~13% recurring) | 95% of all of FY2025, with 5 months still to run |
| Gross Margin | 1H2026 vs 1H2025 | ~60% vs ~65% | 🚩 -5pp, sales mix, FX, raw material impairment |
| Underlying EBITDA | FY2025 vs FY2024 | $36.5m vs $(4.0)m | +$40.5m swing, % not meaningful (prior period was a loss) |
| Underlying PBT | FY2025 vs FY2024 | $33.3m vs $(2.1)m | +$35.4m swing, % not meaningful (prior period was a loss) |
| Statutory Profit/(loss) after tax | FY2025 vs FY2024 | $3.5m vs $(1.3)m | +$4.8m swing, % not meaningful (prior period was a loss) |
| TTM Net income | To ~mid-2026 | 🚩 $(30.83)m, EPS $(0.04) | Swing back to a substantial loss, implies a ~$32m 1H2026 loss alone (BG Trading estimate) |
| Operating Cash Flow | FY2025 vs FY2024 | $15.9m vs $(62.6)m | +$78.5m swing, % not meaningful (prior period was negative) |
| TTM Operating Cash Flow / FCF | To ~mid-2026 | $14.34m OCF / $(2.79)m FCF | FCF has turned slightly negative on rising capex |
| Cash | 31 Mar 2026 | $223m (no debt stated) | Presentation’s most recent balance-sheet figure |
| Cash / Debt | Late Aug 2026 (market data) | 🚩 $178.5m cash / $16.65m debt | Net cash $161.8m; debt has reappeared after being nil through FY2025/Q1 2026 |
| Shares on issue | Aug 2026 | 924.09m | +0.37% in the past year (minimal recent dilution) |
The headline growth numbers are genuinely exceptional and among the strongest of any ASX-listed technology or defence name: revenue up 276% in FY2025 and a further 74% in 1H2026, with committed FY2026 revenue already at 95% of all of FY2025 with five months still to run. Set against that, gross margin compressed 5 percentage points in 1H2026 and the company appears to have swung from a small FY2025 profit into a substantial 1H2026 loss (TTM net income of roughly -$30.83m implies about a -$32m loss in the first half of 2026 alone, a BG Trading estimate derived by netting the disclosed FY2025 and 1H2025 figures against the market-reported TTM number). That’s the central tension in this stock right now: explosive top-line growth that has not yet translated into durable bottom-line profitability, and margin quality that’s moving the wrong way even as revenue accelerates.
Revenue Growth History (Reported fact)
| Year | Revenue | YoY Growth |
|---|---|---|
| 2021 | $10m | +91% |
| 2022 | $17m | +61% |
| 2023 | $54m | +222% |
| 2024 | $58m | +6% (sharp deceleration) |
| 2025 | $217m | +276% |
| 2026 (outlook) | $250m–$270m | +15% to +25% |
Worth flagging on its own: 2024 growth decelerated to just 6% before the 2025 explosion. This is a genuinely lumpy, tender/contract-driven revenue profile, not a smooth compounding SaaS-like curve, and recurring revenue is still only ~11-13% of the FY2026 book, so most of this remains project and hardware revenue rather than durable subscription income.
3. Earnings Quality
- Swing to a large loss despite revenue growth: TTM net income of -$30.83m against FY2025’s +$3.5m implies the business lost money at a meaningfully higher rate in 1H2026 even as revenue grew 74%, the opposite of the operating leverage story the presentation implies.
- Gross margin compression: 65% to ~60% in 1H2026, partly attributed to a raw material impairment identified during a facility move and ERP transition, an execution issue, not just market softness.
- Underlying vs statutory gap: the presentation leans heavily on “Underlying” EBITDA/PBT figures, explicitly flagged in its own disclaimer as Non-IFRS measures that have not been independently audited or reviewed. Treat with the same caution BG Trading applies to any non-statutory metric.
- Revenue recognition mix: Committed Revenue (used for the FY2026 progress figures) is based on confirmed purchase orders scheduled for delivery, not necessarily revenue already recognised, useful as an order-book indicator but not equivalent to booked sales.
- Unresolved regulatory matter: an ongoing ASIC investigation into 2025 announcements and trading activity is a genuine earnings-quality and governance flag that sits outside anything the company’s own presentation discloses.
Classification: LOW. The revenue growth is real and well-documented, but profitability has moved backwards in the most recent disclosed period, margin compression has an operational cause attached to it, and there’s an open, outcome-unknown regulatory investigation. This is not a clean earnings story right now, regardless of how strong the top line looks.
4. Balance Sheet
- Net cash positive: $161.8m net cash (per latest market data), still a real cushion, and a current ratio of 4.30 (per S&P Global Market Intelligence data) indicates strong short-term liquidity.
- Cash declining, debt appearing: cash fell from $223m (31 Mar 2026) to $178.5m (late Aug 2026), and $16.65m of debt has appeared where the presentation states “no debt” as recently as Q1 2026, a directional change worth watching, even though the amount is small relative to the balance sheet.
- Free cash flow has turned slightly negative (TTM $(2.79)m) as capex has risen ($17.14m TTM) to support the global operational build-out (regional hubs, manufacturing, headcount).
- Dilution history: DRO raised $120m via an underwritten placement in August 2024, issuing 100m+ new shares while the stock traded near its highs. Recent share count growth has been minimal (+0.37% over the past year), but the precedent exists if the company needs capital again.
Classification: ADEQUATE. Still net cash positive with decent liquidity, but the direction of travel (declining cash, reappearing debt, negative FCF) is worse than the presentation’s own “no debt, $223m cash” framing suggests, because that framing is now roughly five months stale.
5. Growth
- Past: revenue +276% FY2025, +74% 1H2026, among the strongest growth profiles on the ASX.
- Current: that growth has come with a swing to a substantial net loss and margin compression, not a clean acceleration.
- Future (confirmed pipeline): $206m of FY2026 committed revenue (95% of all of FY2025) with five months still to run, plus $26m of FY2027 committed revenue already booked and growing, plus a case study showing individual military end-user orders scaling from $40-80k to $1.2-3.6m over an 8-year relationship (company’s own illustrative example, not guaranteed to repeat for every customer).
Trend classification: ACCELERATING on revenue, but the earnings-quality concerns in Section 3 mean this is a growth story that has not yet proven it converts to durable profit at scale.
6. Order Book / Pipeline Coverage
FY2026 Committed Revenue stood at $206m as at 28 Jul 2026 against a $250-270m full-year outlook, meaning roughly 76-82% of the low-to-high guidance range is already covered by confirmed purchase orders with five months of the year remaining, a genuinely strong coverage position. Material single-contract announcements through the year ($21.7m in Feb, $19.3m plus $5.6m in options in Jun, $23.2m in Jul) show continued order flow rather than a one-off lump. A large European program selection is reportedly expected later in 2026 and would be a meaningful incremental catalyst if won. None of this is guaranteed revenue until delivered and recognised, and the company’s own materials note forward-looking statements involve inherent risks and uncertainties outside its control.
7. FY2026/FY2027 Projection
FY2026 is not yet complete (DRO’s financial year ends 31 December), so this is a genuine forward projection, not a restatement of an already-reported year. Company guidance: FY2026 revenue $250-270m (+15-25% on FY2025), no formal EBITDA or NPAT guidance disclosed in the supplied materials. Company targets a blended gross margin of ~65% for the full year, which implies 2H2026 margin needs to recover meaningfully above the 60% seen in 1H2026, an assumption to watch, not a certainty. FY2027: $26m of committed revenue already booked and growing, with an increasing mix of hardware, software, services and warranty income; RfAI-3 and RfRecon next-generation product launches are scheduled to commence 3Q2026 through 2027 and are a real, dated product catalyst.
| Scenario | FY2026 Revenue | Key assumption (BG Trading estimate unless noted) |
|---|---|---|
| Bear | ~$250m (low end of guidance) | Margin stays near 60%, 1H2026-style loss continues into 2H, ASIC investigation overhang persists or worsens. |
| Base (company guidance midpoint) | ~$260m | Committed revenue converts as scheduled; margin partially recovers toward the low-60s%, loss narrows but full-year profitability is not assured. |
| Bull | ~$270m+ (top of guidance or beyond) | European program win converts in 2H, gross margin recovers toward the ~65% target, next-gen product launches add incremental revenue. |
8. Valuation
Using the live chart price of ~$1.76 and 924.09m shares on issue.
| Market Cap | ~$1,626m (~$1.63bn) |
| Net Cash | ~$161.8m |
| Enterprise Value | ~$1,464m (~$1.46bn) |
| EV / FY2026 Revenue Guidance (midpoint $260m) | ~5.6x |
| EV / FY2025 Underlying EBITDA ($36.5m) | ~40x, and this trailing figure predates the 1H2026 swing to loss, so its quality is questionable going forward |
| P/E | Not meaningful, TTM net loss |
| Average analyst price target | ~$2.70, “Buy” consensus (~53% implied upside from current price), though individual ratings genuinely diverge from Sell to Buy |
| 52-week range | $1.63 – $6.71 (current price sits near the low end of that range) |
At roughly 5.6x forward revenue for a company that just swung to a substantial loss and is under regulatory investigation, this is not a statistically cheap stock even after a ~74% fall from its highs; it’s still priced for a growth-and-recovery story to play out. One independent analysis (Simply Wall St) argues the stock “could be 26% overvalued” even after the guidance reaffirmation. Classification: Fair to Expensive, depending on whether 2H2026 margin recovery and the European program decision play out as the bull case assumes.
10. Macro
The macro backdrop is genuinely and unusually supportive, and well-sourced in the presentation: NATO has committed US$40bn to counter-drone capabilities over five years, the EU’s Re-Arm Europe plan totals €800bn, the UK has committed £790m to integrated air/drone/missile defence, the US 2027 budget request includes US$21bn for munitions and C-UAS with a further US$900m already committed for 2026 via JIATF-401 (a program DRO is directly on), and Australia has allocated up to A$7bn over ten years for C-UAS and missile defence. This is a real, multi-year, government-funded demand tailwind specific to DRO’s category, not a general market narrative. Classification: Strongly Supportive, though reliant on continued political will and budget execution across multiple governments, which is a real, if lower-probability, macro risk of its own.
11. Industry / Thematic
Counter-drone/C-UxS is a genuinely expanding category: combined military/government (US$35bn) and local/commercial (US$28bn) TAM against DRO’s current ~$217-270m revenue run rate implies very low market penetration and a long runway if the company continues executing. Commercial demand (airports, prisons, critical infrastructure, major events) is a real and growing secondary market beyond the primary military thematic, evidenced by rising incident counts (100+ monthly US airport drone reports, 1,712 UK prison drone incidents in 2024/25, up 43% YoY). Classification: Expanding, with DRO positioned as a category leader, though competitive intensity from larger defence primes (Anduril, Thales, and others partnering into the space) is a real and growing consideration as government budgets scale up and attract bigger players.
12. Catalysts
| Horizon | Catalyst | Importance | Status |
|---|---|---|---|
| 0-3mo | Large European program selection decision | High | Reported as expected later in 2026, timing not confirmed by the company |
| 0-6mo | RfAI-3 / RfRecon next-generation product launches | Moderate-High | Confirmed to commence 3Q2026 through 2027 |
| Ongoing | ASIC investigation update or resolution | High | Outcome and timing unclear |
| 6-12mo | FY2026 full-year result, gross margin recovery test | High | Confirmed, FY ends 31 Dec 2026 |
| Ongoing | Conversion of government funding commitments (NATO, EU, US, Australia) into firm DRO orders | Moderate-High | Ongoing, multi-year |
13. Risk
- Regulatory/governance: ongoing ASIC investigation into 2025 announcements and trading activity, outcome unclear, and not disclosed in the company’s own investor presentation. Probability: already occurring. Impact: High.
- Earnings quality: swing to an estimated ~$32m 1H2026 net loss alongside 74% revenue growth, plus 5 percentage points of gross margin compression tied partly to an operational impairment. Probability: already occurred. Impact: High.
- Financial trend: cash declining ($223m to $178.5m), small debt reappearing, free cash flow turned slightly negative. Probability: already occurred. Impact: Medium.
- Revenue lumpiness: 2024 growth decelerated sharply to +6% before the 2025 explosion; tender/contract-driven revenue can disappoint in any given period. Probability: Medium. Impact: Medium.
- Valuation: ~5.6x forward revenue and ~40x trailing EBITDA (of questionable ongoing quality) is not statistically cheap even after the drawdown. Probability: Medium. Impact: Medium.
- Dilution precedent: a $120m capital raise with 100m+ new shares issued in 2024 shows the company will raise equity when it needs to; not currently signalled, but a real precedent. Probability: Low near-term. Impact: Medium-High if triggered.
- Macro tailwind risk (favourable): demand is underpinned by genuine, dated, multi-government funding commitments, reducing (without eliminating) pure-thematic risk relative to a story with no funding behind it.
Greatest risk of permanent capital loss: the ASIC investigation combined with the swing to a large 1H2026 loss. If the investigation surfaces findings that call into question prior disclosures, or if the loss trend continues into 2H2026 and the FY2026 result disappoints against guidance, both the earnings story and the market’s trust in company-reported “Underlying” metrics could deteriorate quickly from an already-elevated valuation.
14. Technical Analysis (delegated to the BGS 20 Technical skill)
Trend & Moving Averages
- Short-term: turning constructive, today’s strong green session reclaimed the EMA9 (~$1.77) after a month of tight, low-volatility consolidation.
- Medium-term: still bearish, SMA40 (red, ~$1.98) is declining and sits above price, the real hurdle before this is a clean medium-term trend change.
- Long-term: bearish, SMA250 (magenta, ~$3.22) is nearly double the current price.
SMA250 Technical Valuation Band
(1.76 − 3.22) / 3.22 ≈ -45.4% — Deep Discount band, bordering Extreme. Per the framework this alone isn’t a buy signal; it needs the discount to be tested and held, which is what appears to be happening here.
Price Structure
May high (~$3.60) → sharp ~58% crash to a June low (~$1.50) → failed relief rally to ~$2.30 in early August → sold back down and retested the same $1.50-1.65 zone a second time through August without breaking it → recent volatility contraction and a green breakout session above EMA9. That’s a genuine two-touch support test with tightening ranges. Classify: Basing / Improving.
Support & Resistance
- Support: $1.65-$1.50, tested twice (June, August), Moderate-Strong.
- Resistance: SMA40 (~$1.98) is the near-term hurdle; $2.30-2.40 (the failed early-August rally high, matches the drawn BGS 20 Target) is the real test beyond that.
RSI
42.76%, recovering off an oversold dip (~28%) in mid-August. A declining trendline connects RSI peaks since May; that momentum structure hasn’t broken yet, though the August RSI low held roughly level with the June low even as price found support, a mild, not clean, bullish divergence.
Volume
The rally to $2.30 in early August came on rising green volume (genuinely constructive), but the pullback back to support also carried real red volume, a two-way, not a clean accumulation signature. Volume has tapered into the recent base, consistent with contraction ahead of a decision point.
Post-Shock Reversion Setup check
Doesn’t apply, and not just on a technicality: RSI is at 42.76%, already out of oversold territory, so condition 4 (RSI below 30) fails outright. On conditions 1-2, this fundamentals work now surfaces exactly the kind of unresolved issue the rule is built to catch: an open ASIC investigation is a live, unresolved matter, not a confirmed one-off, so even a future oversold retest would need that investigation resolved before this could genuinely qualify as a Post-Shock Reversion Setup.
Entry, Stop, Target
| Stop Loss | $1.65 (below the recent higher-low shelf, a real structural stop) |
| Entry (current) | ~$1.76 → Risk 6.25% |
| BGS 20 Target | $2.40 (matches the tested early-August high) → Reward 36.4% |
| Risk/Reward | ≈5.8:1 — excellent on paper, though SMA40 (~$1.98) sits between entry and target as a real intervening test |
Technical Verdict: Qualifies With Conditions. Trade Quality: ★★★ Good. Technical Risk: Moderate-High, the base is only about a month old and today is one green session, not confirmed reversal. Wants a hold above EMA9 for a few more sessions and ideally a volume-backed reclaim of SMA40 before this is a clean Qualifies.
15. Investor Suitability
Classification: AGGRESSIVE / SPECULATIVE, reduced size. The technical setup is genuinely more constructive than a typical crash (a real, twice-tested support level with a strong R:R), which separates this from a “does not qualify” case. But the earnings-quality deterioration and the open ASIC investigation, neither disclosed in the company’s own materials, mean this is not suitable as a core, full-size, or long-term-conviction position until both resolve with more clarity. Opportunity type: SPECULATIVE POSITION / short-to-medium-term trade around the base and the near-term catalysts (European program decision, product launches), not a long-term investment case on the current information.
16. BGS 20 Score
Fundamentals50 × 15% = 7.50
Growth60 × 10% = 6.00
Balance Sheet55 × 10% = 5.50
Valuation35 × 20% = 7.00
Technical55 × 10% = 5.50
Catalysts65 × 10% = 6.50
Industry/Macro75 × 10% = 7.50
Risk/Reward40 × 15% = 6.00
Weighted sum ÷ 1.00 (all categories assessed)52 / 100
Score band: 52, SPECULATIVE (50-59). The strongest contributors are Industry/Macro (a genuinely well-funded, expanding thematic) and the confirmed order-book Catalysts. The biggest drags are Valuation (still priced for growth despite the loss) and Risk/Reward (dragged down specifically by the open ASIC investigation and the swing to loss), which together carry 35% of the weighting.
17. BGS 20 Verdict
Speculative Buy — Reduced Size
A genuine basing setup on a genuinely well-funded thematic, next to two risks the company’s own presentation doesn’t mention
DroneShield is a real category leader in a category with unusually well-documented, multi-government funding behind it, and the chart shows a genuine, twice-tested support level with an excellent risk/reward on paper (~5.8:1 to the $2.40 target from current levels). That combination is why this clears the bar for a Speculative Buy rather than a Watchlist or Avoid. But it comes with two flags the investor presentation itself is silent on: an unresolved ASIC investigation into 2025 announcements and trading activity, and a swing from FY2025 profitability into an estimated ~$32m 1H2026 loss alongside real gross margin compression. The BGS 20 score of 52 sits at the low end of the Speculative band for exactly that reason.
This upgrades toward a cleaner Qualifies once the base holds for more sessions with a volume-backed reclaim of SMA40, and once there’s more clarity on either the ASIC investigation or the FY2026 full-year margin recovery. Size accordingly, and respect the $1.65 stop without exception given how much is still genuinely unresolved here.
Would BG Trading buy at the current price (~$1.76)?
At reduced size, yes, on the strength of the twice-tested support and the R:R, but not at full conviction given the open ASIC investigation and the earnings-quality deterioration.
Biggest reason to own it?
A category-leading counter-drone business with explosive, well-funded demand and a chart that has genuinely held support twice, not just crashed once.
Biggest reason not to?
An unresolved ASIC investigation and a swing to a substantial 1H2026 loss, neither of which the company’s own promotional materials disclose.
What invalidates the bullish thesis?
A break and hold below $1.65, an adverse ASIC finding, or an FY2026 result that misses guidance with margin still stuck near 60%.
Single most important catalyst?
The FY2026 full-year result and whether gross margin genuinely recovers toward the ~65% target, alongside any update on the ASIC investigation.
Technically discounted, fundamentally undervalued, both, or neither?
Technically discounted and holding a genuine support level; fundamentally not clearly undervalued, ~5.6x forward revenue on a loss-making TTM base isn’t statistically cheap.
Trade or long-term investment?
A trade around the base and near-term catalysts for now, not a long-term conviction position until the two open questions above are resolved.
:
:
Disclaimer. The information contained in this report is provided by BG Trading Australia (ACN 161943228, License 4901880) for general informational purposes only and does not constitute personal financial product advice. It has been prepared without taking into account your objectives, financial situation, needs, or risk tolerance, and should not be relied upon as a substitute for independent professional advice tailored to your circumstances. Nothing in this report constitutes an offer, solicitation, or recommendation to buy, sell, or hold any financial product.
All technical levels, targets, and commentary reflect a point-in-time interpretation of publicly available chart data and are inherently speculative; markets are volatile and unpredictable, and no methodology, including the BGS 20 framework, can guarantee any particular outcome. Past performance is not, and should not be treated as, an indicator of future performance. Fundamental figures beyond FY2025 are drawn partly from the company’s own investor presentation (which is promotional, forward-looking, and based on non-independently-audited “Underlying” measures per its own disclaimer) and partly from third-party market data sources for periods not yet covered by statutory accounts; both should be independently verified before acting. To the maximum extent permitted by law, BG Trading Australia, its directors, employees, and agents disclaim all liability, whether direct or indirect, for any loss or damage arising from reliance on this report, including any errors, omissions, or inaccuracies in the information provided, and any decision made or action taken on the basis of it. You acknowledge that trading and investing carry inherent risk, including the risk of loss of capital, and that you act on this information entirely at your own discretion and risk. BG Trading recommends you obtain independent, licensed financial and taxation advice before making any investment decision.